MedPath

Air Optix® Night and Day® Aqua Continuous Wear

Conditions
Refractive Errors
Interventions
Device: Lotrafilcon A contact lenses
Device: Balafilcon A contact lenses
Registration Number
NCT05992675
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this retrospective, Post-Market Clinical Follow-Up (PMCF) study is to assess the long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as 30 days of continuous wear for vision correction.

Detailed Description

This is a non-interventional/observational study designed as a retrospective chart review. Study sites will identify charts within their existing databases in a fair and consistent manner. Subjects/charts meeting the eligibility criteria will be enrolled in the study.

The study is designed with one period. The duration of the period includes the Baseline Visit and the Year 3 Visit as follows:

* The Baseline Visit is defined as the first office visit where an eye care professional provided an in-person office biomicroscopy exam to the subject, before or during which a contact lens prescription for AONDA or PureVision 2 (PV2) was released.

* The Year 3 Visit is defined as a visit which occurred 3 years (-2/+8 months) since Baseline during which period the subject was wearing AONDA contact lenses or PV2 contact lenses and a contact lens examination was performed.

The data collection period is defined as any approximately 3-year timeframe since and including 2009.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
1140
Inclusion Criteria
  • Manifest refraction cylinder less than or equal to 0.75 diopter in each eye at baseline
  • Best corrected visual acuity of 20/25 or better in each eye at baseline
  • At the time of Year 3 Visit, subject was prescribed and wearing AONDA or PV2 contact lenses in both eyes in a 30-day continuous wear modality for at least approximately 3 years
  • Baseline Visit and Year 3 Visit charts available

Key

Exclusion Criteria
  • Any recurrent history or active anterior segment infection, inflammation, abnormality, or disease contraindicating regular contact lens wear present at baseline
  • The use of systemic or ocular medications contraindicating regular contact lens wear at baseline
  • History of refractive surgery or irregular cornea
  • Slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear at baseline

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
AONDA contact lensesLotrafilcon A contact lensesLotrafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
PV2 contact lensesBalafilcon A contact lensesBalafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
Primary Outcome Measures
NameTimeMethod
Distance visual acuityYear 3

The subject's chart will be reviewed for distance visual acuity.

Incidence of corneal infiltrative eventsUp to Year 3

The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the Baseline Visit exam.

Incidence of microbial keratitisUp to Year 3

The subject's chart will be reviewed for incidences of microbial keratitis occurring after the Baseline Visit exam.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (8)

Complete Eye Care of Medina

🇺🇸

Medina, Minnesota, United States

Vision Health Institute

🇺🇸

Orlando, Florida, United States

Sacco Eye Group

🇺🇸

Vestal, New York, United States

Koetting Associates

🇺🇸

Saint Louis, Missouri, United States

Smith Bowman Ophthalmology

🇺🇸

Salt Lake City, Utah, United States

Complete Family Vision Care

🇺🇸

San Diego, California, United States

Jackson Health Community Center

🇺🇸

Miami, Florida, United States

Pearle Vision

🇺🇸

Jacksonville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath